glp-1 name brands 5 trends to expect in 2026: Expanded uses, oral options, and more Market Overview: GLP-1 Agonists and
Description
Look at the tier and check PA, step therapy, and quantity limits
Evidence for Cardiovascular Safety The DPP-4 inhibitors have not demonstrated any sustained or clinically significant reduction in other cardiovascular risk factors, such as blood pressure or lipids
Can I switch from injections to tablets
Snchez MB, Callaghan MJ, Selfe J, Twigg M, Smith T
Drug interactions are another critical consideration
Glucose-dependent insulinotropic polypeptide (GIP) and GLP1 are Incretin hormones
